Form 4 for NAMS NewAmsterdam Pharma Co N.V.
Accepted 2024-08-22 00:00:00 ET · period of report 2024-08-20 · accession 0000950170-24-099871 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-08-22 | 2024-08-20 | NAMS | Davidson Michael H. | CEO, Dir | P - Purchase | $16.27 | +5,000 | 209.8K | +2% | +$81.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2024-08-20 | P | A | 5,000 | $16.27 | 209,784 | D | — | — |